STAT+: Novartis doubles down on molecular glue strategy

STAT PlusNewsletterThe Readout Novartis doubles down on molecular glue strategy Seniors’ drug costs rise sharply, Enliven’s leukemia drugs, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanJune 11, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Medicare drug spending is climbing faster than expected, driven by surging use of GLP-1 medicines and ongoing fallout from Democrats’ Part D redesign.Advertisement Also, Enliven’s leukemia drug has encouraging early data, Novartis is expanding its molecular glue ambitions, and SonoThera raised $125 million to advance an ultrasound-based approach to gene delivery. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech June 11, 2026 STAT Plus: Enliven Therapeutics’ leukemia drug shows promise in new study Adam's Biotech Scorecard June 11, 2026 STAT Plus: ‘Synthetic lethality’ could trigger another round of biotech M&A Advertisement The Readout June 10, 2026 STAT Plus: Hope for Kendall Square’s lab market D.C. Diagnosis June 9, 2026 STAT Plus: Trump’s health care affordability czar takes aim at hospitals The Readout June 9, 2026 Gilead and Merck’s latest trial success and flop Subscriber Picks